Takeda Pharmaceutical Reports Revenue Growth in April–June 2026 Quarter, Boosted by Overseas Sales on Weaker Yen

時事通信··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

Takeda Pharmaceutical posted higher revenue and operating profit in its consolidated results for the April–June 2026 quarter. The main driver was an expansion in overseas sales due to the weaker yen. The figures are based on International Financial Reporting Standards, though detailed numbers have not been disclosed.

Impact on assets 2

Biotech & Genomic Medicine▲ · 1 stocks
Others▲ · 1 stocks
© 2026 MarketIVNews